Evidence map›Paper›PMID 41993256›Full record

ArticlebioRxiv : the preprint server for biology2026

Levosimendan inhibits HIV-1 infection in myeloid cells in the RIOK1-dependent manner.

Jinshan He, Jie Ma, Youngmin Park, Dawei Zhou, Xu Wang, Guillaume N Fiches, Kateepe Asn Shanaka, Thurbu T Lepcha, Yan Liu, Suha Eleya and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jinshan HeDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Jie MaDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Youngmin ParkDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Dawei ZhouDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Xu WangDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Guillaume N FichesDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Kateepe Asn ShanakaDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Thurbu T LepchaDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Yan LiuDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Suha EleyaDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Netty G SantosoDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Wen-Zhe HoDepartment of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Jian ZhuDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.

Funding

Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine UsersR01DA059538 · NIDA · OHIO STATE UNIVERSITY · PI Wei Jiang, Jian Zhu · 2023 to 2026
$2.9M
Target Host Epigenetic Regulation of HIV Proviruses to Reinforce Viral Deep Latency in MicrogliaR01MH134402 · NIMH · OHIO STATE UNIVERSITY · PI HO, WENZHE, ZHU, JIAN · 2023 to 2025
$2.2M
Antagonize Host Survival and Immune Escape Mechanisms for Elimination of HIV Viral ReservoirsR56AI181631 · NIAID · OHIO STATE UNIVERSITY · PI LING, BINHUA "JULIE", ZHU, JIAN · 2024 to 2024
$842k
Role of RNA Methylation in Regulating HIV Proviral ExpressionR56AI157872 · NIAID · OHIO STATE UNIVERSITY · PI ZHU, JIAN · 2021 to 2021
$374k
NIAID NIH HHS R56 AI157872NIAID NIH HHS R56 AI181631NIDA NIH HHS R01 DA059538NIMH NIH HHS R01 MH134402
6 · The paper itself

Abstract

Despite of the highly potent antiretroviral therapies, HIV-1 establishes persistent infection and causes chronic inflammation in AIDS patients. Beyond CD4+ T cells, HIV-1 infects myeloid cells, including circulating monocytes and tissue-resident macrophages, and integrates with host genomes to form stable viral reservoirs. To achieve a functional HIV cure, latency-promoting agents (LPAs) have been developed for the "block-and-lock" strategy to reinforce deep HIV-1 latency and permanently silence proviruses. However, most LPAs have been tested mainly in CD4

Indexed as

HIVlatencylevosimendan (LSM)myeloid cellsRIOK1

Identifiers

PMID41993256
PMCPMC13081825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.